^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
02/08/2018
Excerpt:
Herzuma should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.